NGN-401 is Neurogene's lead and essentially only pipeline asset — a one-time gene therapy for Rett syndrome, a severe rare neurological disorder affecting ~1 in 10,000 females. The drug has generated strong efficacy signals in Phase 1/2 (100% of 10 participants showed functional improvements, 35 developmental milestones gained across the group) and has secured FDA Breakthrough Therapy, RMAT, Fast Track, and Orphan Drug designations. The Embolden registrational trial completed dosing in June 2026, with topline data expected 2H 2027. The main rival is Taysha Gene Therapies' TSHA-102, while Acadia's Daybue (trofinetide) is the only currently approved Rett therapy but is a daily symptomatic treatment, not a one-time gene therapy. Cash of $243.2M (Q1 2026) provides runway into Q1 2028. Analyst consensus is Strong Buy with a mean price target of $80 (~150% upside).
FYCOMPA (perampanel) is an anti-epileptic drug originally developed by Eisai and first FDA-approved in 2012. Catalyst Pharmaceuticals acquired U.S. commercial rights in January 2023 for $160M upfront. The drug generated $137.3M in 2024 revenue for Catalyst, but its patent on tablets expired May 2025 (three generics now on market) and oral suspension patent expired December 2025 (one generic). FYCOMPA is now a declining asset — Catalyst guided just $40-45M in 2026 revenue and discontinued active promotion. The broader company story shifted in May 2026 when Angelini Pharma agreed to acquire Catalyst for $31.50/share (~$4.1B), with a shareholder vote set for July 2026 and expected close in Q3 2026.
-
NXP900 is Nuvectis Pharma's lead (and now sole) clinical-stage asset — an oral SRC/YES1 kinase inhibitor with a novel "type 1.5" mechanism that differentiates it from older SRC inhibitors like dasatinib. The drug has completed Phase 1a dose-escalation safely in 33 patients and is now in Phase 1b testing as monotherapy and in combination with osimertinib for EGFR-mutant NSCLC. After the failure and discontinuation of sister drug NXP800 in ovarian cancer, Nuvectis is now a de facto single-asset company with ~$25M cash and a $150M shelf offering on file. Analyst consensus is strongly bullish (10 Buy vs 1 Hold, mean PT ~$29), and major institutions (Fidelity, Wells Fargo, Morgan Stanley, Bank of America) have accumulated positions. The pivotal near-term catalyst is the preliminary Phase 1b readout expected in summer 2026 — a binary event that could either validate the drug's promise or leave the company struggling for credibility and capital.
Explore drug → -
NXP100 (HSK39297) is a once-daily oral complement Factor B inhibitor licensed by Nuvectis Pharma (NASDAQ: NVCT) from China's Haisco Pharmaceutical for ex-China rights in a deal worth up to $1.42B. Two China NMPA marketing applications are under review for PNH, a Phase 3 IgAN trial is ongoing, and Phase 2 LN data is accumulating. The drug competes directly with Novartis's already-approved iptacopan (Fabhalta) in the same target and indications. NVCT raised $100M in a dilutive June 2026 offering to fund development, and the stock has run sharply (+180% in one month). The China PNH approval decision is the nearest binary catalyst, but ex-China commercialization is years out and requires bridging studies.
Explore drug →
-
Atumelnant (CRN04894) is Crinetics' second pipeline drug — a first-in-class, once-daily oral ACTH receptor antagonist in late-stage development for congenital adrenal hyperplasia (CAH) and early-stage for ACTH-dependent Cushing's syndrome. Phase 2 data showed rapid, sustained reductions in disease biomarkers (up to 80% reduction in androstenedione) and normalized steroid dosing in 88% of patients. A pivotal Phase 3 trial (CALM-CAH) began enrollment in December 2025. Atumelnant faces competition from Neurocrine's already-approved CRENESSITY (crinecerfont), but early comparisons suggest a potential efficacy advantage. Crinetics already has one commercial product (PALSONIFY for acromegaly, $10.3M Q1 2026 revenue), providing a revenue base and reducing single-point-of-failure risk. Analyst consensus is Strong Buy with a mean price target implying ~123% upside.
Explore drug → -
PALSONIFY (paltusotine) is Crinetics Pharmaceuticals' first approved and launched product — a once-daily oral treatment for acromegaly, a rare endocrine disorder. The FDA approved it on Sept 25, 2025 (stock surged 30.5% that day), and the EU followed on April 27, 2026. Early commercial traction is strong: Q4 2025 net revenue of $5.4M, Q1 2026 revenue of $10.3M, with >200 patient starts and 125+ unique prescribers. The key competitive edge is that it's the only oral once-daily therapy in a market historically dominated by injectables (Novartis' Sandostatin, Ipsen's Somatuline). S&P Global projects blockbuster peak sales of ~$1B by 2034. The pipeline expansion into carcinoid syndrome (Phase 3 CAREFNDR) adds upside optionality. The stock at ~$37 trades well below the mean analyst target of ~$83, with strong institutional support (FMR, Vanguard, BlackRock) and a strong-buy consensus (20 buys, 2 holds, 0 sells). Risks include commercial execution in a rare-disease market, competition from established injectable therapies, pipeline setbacks, and the company's pre-profitability status.
Explore drug →
Evorpacept is ALX Oncology's lead investigational CD47-blocking fusion protein, positioned as a potentially safer alternative in a drug class that has seen major setbacks (Gilead's magrolimab partial clinical hold, AbbVie/I-Mab termination). Phase 2 data in HER2+ gastric cancer showed a meaningful benefit over standard of care, earning FDA Fast Track designation. The drug is now in a Phase 2/3 registrational trial (ASPEN-06) with the Phase 3 portion still enrolling. A second Phase 2 trial (ASPEN-09-Breast) targets HER2+ breast cancer with interim data due mid-2027. The stock trades near $2.07 with a mean analyst target of $4.60 (~152% upside), and the company has ~$169M cash funding operations through 1H 2028. Strong institutional buyers entered in Q1 2026 (RA Capital, Blackstone, Driehaus). However, the CD47 field carries a history of clinical failures, and evorpacept remains years from potential commercialization with no near-term binary catalyst.
WINREVAIR (sotatercept) is a first-in-class activin signaling inhibitor approved by the FDA in March 2024 and the EMA in August 2024 for pulmonary arterial hypertension (PAH). It generated $525M in Q1 2026 sales and is on a rapid growth trajectory toward analyst peak sales estimates of $3-7.2B by 2035. Three Phase 3 trials (STELLAR, ZENITH, HYPERION) all met primary endpoints with robust risk reductions of 76%. A Phase 2 proof-of-concept in HFpEF (CADENCE) was positive, opening a much larger addressable market. However, for Merck — a $325B market cap giant with $65B+ in annual revenue — WINREVAIR is an important growth driver but not a single-stock-defining binary. The stock price already reflects the approval; the thesis now hinges on commercial execution and label expansion success.
LEQEMBI IQLIK is the subcutaneous (at-home injection) version of lecanemab, an anti-amyloid antibody for early Alzheimer's disease co-developed by Eisai and Biogen. Already approved by the FDA in August 2025 for maintenance dosing (weekly at-home injection after 18 months of IV therapy), it's the first and only at-home anti-amyloid treatment. The key near-term catalyst is the August 24, 2026 PDUFA decision on expanding the label to include starting-dose use, which would allow patients to begin treatment with the at-home injection from day one rather than after 18 months. Leqembi generated ~JPY 88 billion (~$580M) in global revenue in FY2025, and IQLIK is central to Biogen's growth narrative. The drug carries a boxed warning for ARIA (brain swelling/bleeding), a class-wide safety concern. Biogen stock has rallied ~71% over 12 months and trades near 52-week highs, with a mean analyst price target of ~$220.
Cytisinicline is a smoking-cessation drug candidate from Achieve Life Sciences (ACHV, ~$640M market cap). Two positive Phase 3 trials (ORCA-2, ORCA-3) showed statistically significant quit rates vs placebo. The FDA accepted the NDA in September 2025 with a June 20, 2026 PDUFA date, but issued a Complete Response Letter on June 22 citing manufacturing deficiencies at a third-party facility — not efficacy or safety problems. The company has transferred manufacturing to Adare Pharma Solutions and plans to resubmit in Q4 2026, targeting potential approval in H1 2027. Analysts remain overwhelmingly bullish (13 Buy/Strong Buy vs 1 Hold; mean PT $13.80). The stock actually rose 7.3% on CRL day, reflecting confidence the manufacturing issue is fixable. However, a ~99M-share S-3 overhang and the need to pay for the new manufacturing facility represent dilution and execution risks.
RYZUMVI (phentolamine ophthalmic solution 0.75%) is an FDA-approved eye drop for reversing pharmacologically induced pupil dilation. It was developed by Ocuphire Pharma, which acquired Opus Genetics in October 2024, renamed the combined entity Opus Genetics, and now trades as IRD on Nasdaq. The drug is marketed in the US by Viatris. Beyond the approved indication, RYZUMVI has positive Phase 3 data in presbyopia (VEGA-3, June 2025) and night vision disturbances after LASIK (LYNX-2, June 2025). The FDA accepted a supplemental NDA for presbyopia with a PDUFA goal date of October 17, 2026. If approved, RYZUMVI would enter a growing but competitive presbyopia eye-drop market currently led by AbbVie's Vuity (pilocarpine) and newer entrants Qlosi and Yuvezzi. Opus Genetics' primary value driver, however, is its gene therapy pipeline for inherited retinal diseases; RYZUMVI provides revenue through the Viatris cost-sharing and royalty arrangement ($14.2M in 2025).
Tebipenem pivoxil hydrobromide (Utebzi) is the first FDA-approved oral carbapenem antibiotic, approved June 17, 2026 for complicated UTIs in adults. Developed by Spero Therapeutics (Nasdaq: SPRO) and licensed to GSK in 2022 for $66M upfront (up to $525M in milestones + tiered royalties), after the FDA had initially issued a Complete Response Letter in 2022 requiring an additional Phase 3 trial. The stock surged ~245% when the PIVOT-PO Phase 3 trial hit in mid-2025 and rose another ~16% on approval, but has since settled. With the rest of Spero's pipeline struggling (SPR720 Phase 2a missed its endpoint, SPR206 halted), the company's value now hinges entirely on its GSK partnership and Utebzi's commercial trajectory — a less binary, more gradual story than the pre-approval days.
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody and Summit Therapeutics' sole clinical-stage asset, licensed from Chinese biotech Akeso. Already approved in China, its BLA for EGFR-mutated NSCLC is under FDA review with a PDUFA decision by November 14, 2026 — a high-stakes binary for a single-asset company. The drug has generated mixed clinical data: strong PFS results across multiple trials, but overall survival (OS) missed pre-specified thresholds in both the global HARMONi trial and the HARMONi-2 head-to-head vs Keytruda. However, the HARMONi-6 trial demonstrated a positive OS signal (34% risk reduction) presented at ASCO 2026. After a volatile 2026 — interim PFS miss, $500M dilutive offering, and insider buying of ~$100M — the stock trades near its 52-week low with a mean analyst target implying ~46% upside.
Zanzalintinib (XL092) is Exelixis's next-generation tyrosine kinase inhibitor and the company's most important pipeline asset, developed as a successor to its blockbuster drug cabozantinib (Cabometyx). The NDA for zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer was accepted by the FDA with a PDUFA date of December 3, 2026. The Phase 3 STELLAR-303 trial produced split results — statistically significant OS improvement in the full ITT population (HR 0.80, P=0.0045) but a non-significant trend in the pre-specified non-liver-metastases subgroup (HR 0.83, P=0.1185), creating real approval uncertainty. The company is also evaluating zanzalintinib across multiple other solid tumor types (neuroendocrine tumors, RCC, NSCLC, prostate cancer). Exelixis currently generates over $2B annually from Cabometyx, giving the stock a valuation floor, but zanzalintinib approval would unlock a substantial new growth vector. The stock trades near its 52-week high with the mean analyst target below the current price, elevated short interest, recent insider selling, and a downgrade from Truist — reflecting the market's skepticism about the split trial data.
Oxylanthanum carbonate (OLC) is Unicycive Therapeutics' only pipeline asset — a next-generation phosphate binder for dialysis patients with high phosphate levels. The drug's key advantage is a much lower daily pill burden versus existing binders like Fosrenol (lanthanum carbonate). On June 30, 2026, the FDA issued its second Complete Response Letter, again citing unresolved third-party manufacturing deficiencies. The FDA raised no clinical safety or efficacy concerns. The stock crashed ~45% that day to ~$4.69, near its 52-week low of $3.71. All ten analysts still rate the stock Buy/Strong Buy with a mean price target of $41.30, but the approval timeline is now pushed 5-12 months out with no firm next PDUFA date. The company is a single-asset, pre-revenue biotech facing a lengthy, uncertain path to its first commercial product.
mRNA-1010 (brand name: mFlusiva) is Moderna's first non-COVID product to reach an FDA decision, and it is the single most important near-term catalyst for the stock. Two Phase 3 trials demonstrated superiority over standard-dose influenza vaccines in adults 50+, with results published in the NEJM. After a dramatic reversal — the FDA initially refused to file the BLA in February 2026, then reversed course — the agency's advisory committee voted unanimously (9-0) to recommend approval on June 18. The PDUFA goal date is August 5, 2026. The stock has rallied from a 52-week low of $22.28 to ~$71 on the flu vaccine narrative, though analyst consensus remains a Hold with a mean price target of $44.25 — meaning the stock has already overshot consensus expectations. Approval would open a major new revenue stream beyond COVID; rejection (a CRL) would be a severe blow to Moderna's post-pandemic growth story.
YUVIWEL is Ascendis Pharma's third FDA-approved drug, cleared in February 2026 under accelerated approval to increase linear growth in children aged 2+ with achondroplasia. Its key advantage over the only existing treatment (BioMarin's Voxzogo, $927M in 2025 sales) is once-weekly dosing versus daily injection, backed by 7-year orphan drug exclusivity. The stock trades near its 52-week high with a strong-buy analyst consensus (25 buy/strong-buy, 1 hold) and a mean price target ~$292 (~27% upside). However, the drug faces an entrenched competitor, carries accelerated-approval confirmatory-trial risk, and is early in its commercial launch with unproven revenue contribution.
CAN-2409 (aglatimagene besadenovec) is Candel Therapeutics' lead and most advanced immunotherapy — a viral immunotherapy that trains the immune system to fight solid tumors. It has already succeeded in a pivotal Phase 3 trial in localized prostate cancer (745 patients, HR 0.70, p=0.0155 for disease-free survival), with results published in The Lancet Oncology. The company plans to submit a Biologics License Application (BLA) in Q4 2026, making it a pre-revenue, pre-approval biotech with a major near-term catalyst. The drug also showed striking Phase 2 survival data in pancreatic cancer (31.4 vs 12.5 months median OS) and NSCLC. Candel has secured a $130M term loan facility and drawn $50M, giving it runway into early 2028. The stock has strong institutional backing (Fidelity, Baker Bros, RTW Investments) and a mean analyst price target of ~$20 (roughly 2x current levels).
Optune Pax is NovoCure's third FDA-approved Tumor Treating Fields (TTFields) device, cleared in February 2026 for locally advanced pancreatic cancer — the first new treatment in this indication in nearly 30 years. The Phase 3 PANOVA-3 trial showed a modest but statistically significant 2-month median overall survival improvement (16.2 vs 14.2 months) and a 6-month delay in pain progression when added to chemotherapy. The early U.S. launch is promising (169 prescriptions, 90 patient starts in the first 7 weeks), but reimbursement processes will take 1-2 years to fully develop. NovoCure is still unprofitable (Q1 2026 net loss of ~$71M) and carries elevated short interest (~45% short ratio). The commercial ramp and eventual China approval (via Zai Lab) are the key value drivers from here.